Who Paid My Doc
A Phase 3A, Observer-Blind, Randomized, Controlled Study to Demonstrat
Research payments
$1,770,055
Through program year 2025, $1,770,055 in research payments was reported against A Phase 3A, Observer-Blind, Randomized, Controlled Study to Demonstrat, across 249 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $1,770,055 | 249 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Scott Dobson Greenville, SC Named on 18 payments
- Derick Young Nederland, TX Named on 16 payments
- Stephen Jones Greenville, SC Named on 15 payments
- Jason Church Ogden, UT Named on 12 payments
- Daniel Finn Springfield, KY Named on 10 payments
- Joseph Moore Idaho Falls, ID Named on 9 payments
- Carey Chronis Oxnard, CA Named on 9 payments
- John Traynham Charleston, SC Named on 8 payments
- Martin Levinson Bingham Farms, MI Named on 8 payments
- Brent Eberhard Layton, UT Named on 8 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.